<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Cancer Studies and Molecular Medicine</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8F4191DC-98B5-4C58-89B3-8C4C67CBBFC2"><gtr:id>8F4191DC-98B5-4C58-89B3-8C4C67CBBFC2</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Brocklehurst</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AF8E20C3-7DBC-488C-8CA5-CDA09C88D055"><gtr:id>AF8E20C3-7DBC-488C-8CA5-CDA09C88D055</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Mayne</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8886B12A-B4F1-4B95-BE6F-9DE492E7FDA4"><gtr:id>8886B12A-B4F1-4B95-BE6F-9DE492E7FDA4</gtr:id><gtr:firstName>Alison</gtr:firstName><gtr:surname>Salt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7208400B-6791-4400-A90A-059F08720740"><gtr:id>7208400B-6791-4400-A90A-059F08720740</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Marlow</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CBE88ADC-1C2E-4D3E-81A5-7E3104CEBDA7"><gtr:id>CBE88ADC-1C2E-4D3E-81A5-7E3104CEBDA7</gtr:id><gtr:firstName>D</gtr:firstName><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/940F6929-E5F4-41C5-9423-5CA64068C313"><gtr:id>940F6929-E5F4-41C5-9423-5CA64068C313</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9226450"><gtr:id>26B4B0CF-E07E-47CC-8ACD-5BC57089B234</gtr:id><gtr:title>ORACLE follow-up study</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9226450</gtr:grantReference><gtr:abstractText>The ORACLE Children Study is the UK follow-up at 7 years of age of nearly 9000 children whose mothers joined the ORACLE trial in pregnancy. Women with either early broken waters or threatened preterm labour were randomised to antibiotics (erythromycin or augmentin) either singularly or in combination. Research has shown that a proportion of premature births are due to mild, unnoticed infection in the membranes surrounding the baby. Therefore, in theory giving women antibiotics could have beneficial effects on these women and their children
This ORACLE Children Study will look at whether disability (both presence and severity) is reduced in the children of groups of women who took the antibiotics by using a questionnaire to parent s. It will also find out if there are any differences in educational attainment by using the results of the standard National Tests at Key Stage 1 which all 7 year old children in England do.. It is important for both parents and clinicians to know, when faced with a potential premature birth and its consequences, whether antibiotics improve not only survival in the short term but also health and development in the longer term.</gtr:abstractText><gtr:technicalSummary>The sequaelae of preterm birth are a major public health issue. This ORACLE Follow-Up Study presents a unique opportunity to determine is a simple, inexpensive intervention reduces the long-term sequaelae of being born preterm. This proposal is for a follow-up study of 8,942 children at 7 years of age born to women randomised in the UK to the ORACLE Trial. This was a multicentre, pragmatic, double blind placebo controlled trial which tested the hypothesis that the treatment of women in spontaneous preterm labour (SPL) or with preterm, prelabour rupture of the membranes (pPROM) with broad spectrum antibiotics (Augmentin 375mg and/or Erythromycin 250 mg) prolonged pregnancy and improved neonatal mortality and morbidity.

The follow-up study will investigate the effect of the prescription of these antibiotics on the incidence and level of disability at 7 years of age using a parental questionnaire which includes validated questions. It will also determine i) educational achievement by the innovative collection of National Tests at Key Stage 1 and ii) the degree of function in the six domains of sensation, mobility, emotion, cognition, self care and pain. In addition, the incidence of cerebral palsy, epilepsy, respiratory disease, diabetes and death will be described.

The ORACLE Follow-Up Study brings together experts in the field, to undertake a two phase study. The feasibility phase (2 years) will assess whether women can be traced, the response rate to the parental questionnaire and the feasibility of accessing National Tests Key Stage 1 data. The main phase will last a further 4 years.

The ORACLE Follow-Up Study is relatively inexpensive for this type of study, as costs are confined to the administration and management of data collection and analysis.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1993-10-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>4930351</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Cochrane Review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2622BC82-4B01-450B-97C1-EA8EEB5EEE71</gtr:id><gtr:outcomeId>reZZRgx73vL</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20687063</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in Cochrane Review</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>651D71B5-14DD-4C68-9382-9B2A6E812B0A</gtr:id><gtr:outcomeId>543fce2b79d682.56318238</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1ED565CC-E1CC-4245-B01D-AA540E9EE4A2</gtr:id><gtr:title>Unblinding following trial participation: qualitative study of participants' perspectives.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01672e49b6bae2aab68a64125345512f"><gtr:id>01672e49b6bae2aab68a64125345512f</gtr:id><gtr:otherNames>Armstrong N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>ekKNVtduacu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21F5C2A1-290E-4C5C-9154-9252841C87D5</gtr:id><gtr:title>Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac91d594c7e90381df2cf61e9aa41f26"><gtr:id>ac91d594c7e90381df2cf61e9aa41f26</gtr:id><gtr:otherNames>Kenyon S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>LKm31yJD1Ye</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BF15ADE-ABF6-4E47-8688-790A18F3C5E0</gtr:id><gtr:title>Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac91d594c7e90381df2cf61e9aa41f26"><gtr:id>ac91d594c7e90381df2cf61e9aa41f26</gtr:id><gtr:otherNames>Kenyon S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>YqSgfJ4bNDG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76E943CF-8221-4CA8-8BBF-637C2B3977DB</gtr:id><gtr:title>Providing the results of research to participants: a mixed-method study of the benefits and challenges of a consultative approach.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c872a2b157f74c5544699e57d04805a"><gtr:id>5c872a2b157f74c5544699e57d04805a</gtr:id><gtr:otherNames>Dixon-Woods M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>tkBLCUzjYk9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2650DC34-54E4-4144-847E-8FB518656671</gtr:id><gtr:title>Characteristics of children with cerebral palsy in the ORACLE children study.</gtr:title><gtr:parentPublicationTitle>Developmental medicine and child neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c8068e3fbc14cc4061c5160e12bee22"><gtr:id>0c8068e3fbc14cc4061c5160e12bee22</gtr:id><gtr:otherNames>Marlow N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-1622</gtr:issn><gtr:outcomeId>pm_16291_21_22458348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22C231C9-28B8-440C-B90E-C9842EAE97E4</gtr:id><gtr:title>Routine educational outcome measures in health studies: Key Stage 1 in the ORACLE Children Study follow-up of randomised trial cohorts.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4cfff838a1d2c76784b88b2e0a72c01"><gtr:id>f4cfff838a1d2c76784b88b2e0a72c01</gtr:id><gtr:otherNames>Jones DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>Usyh52DaXFY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>919B7AF4-E937-409B-84F4-B595AF3DBEC8</gtr:id><gtr:title>Consent revisited: the impact of return of results on participants' views and expectations about trial participation.</gtr:title><gtr:parentPublicationTitle>Health expectations : an international journal of public participation in health care and health policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a843075daab3cd332349ac62a04d012c"><gtr:id>a843075daab3cd332349ac62a04d012c</gtr:id><gtr:otherNames>Tarrant C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1369-6513</gtr:issn><gtr:outcomeId>56ba30d62d3903.64864379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D97FE39-9F78-4457-98D7-EA34FD544DEF</gtr:id><gtr:title>Has publication of the results of the ORACLE Children Study changed practice in the UK?</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac91d594c7e90381df2cf61e9aa41f26"><gtr:id>ac91d594c7e90381df2cf61e9aa41f26</gtr:id><gtr:otherNames>Kenyon S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn><gtr:outcomeId>CzqzTG2vSwH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06F5DB54-8CFD-40C7-9111-A1BD7D02F91C</gtr:id><gtr:title>The ORACLE Children Study: educational outcomes at 11 years of age following antenatal prescription of erythromycin or co-amoxiclav.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood. Fetal and neonatal edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c8068e3fbc14cc4061c5160e12bee22"><gtr:id>0c8068e3fbc14cc4061c5160e12bee22</gtr:id><gtr:otherNames>Marlow N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-2998</gtr:issn><gtr:outcomeId>58a1dc7f19dc47.33863181</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9226450</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>